Tenderwize
Zurück zur Suche

Open-house drug rebate agreements Brandenburg

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 134 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Brandenburg

57/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

57 / 100

Komplexität

61 / 100

Risikofaktoren

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Eckdaten der Ausschreibung

Öffentlicher Auftraggeber
AOK Nordost - Die Gesundheitskasse
Land
Deutschland
CPV
33600000 - Pharmaceutical products
Frist
Feb 21, 2027

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive drug discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region.
  • Supply-related scope covering pharmacy-prepared parenteral oncology preparations made from finished medicinal products for immediate physician administration to patients.
Vollständige Zusammenfassung anzeigen

Open-house pharmaceutical discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region, covering Bevacizumab, Rituximab and Trastuzumab. The buyer states that every interested pharmaceutical company meeting the published requirements may join on identical, non-negotiable terms and that no supplier selection is made. Contracts are planned from 1 May 2026 to 30 April 2027, subject to earlier termination or automatic suspension if a relevant nationwide or regional discount agreement enters into force. Procurement documents are referenced through the DTVP portal but were not provided for analysis. The structured final deadline is 21 February 2027, while the lot descriptions state that contract conclusion is possible only until 21 February 2026; this material inconsistency must be clarified.

Risiken

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only pharmaceutical companies may participate as potential contract partners.
  • The contract terms are pre-established, identical and not individually negotiable.

Administrative

  • The completed and signed agreement must be submitted together with the completed PZN file named OHV_8c_Brandenburg_Festlegung_[Wirkstoffname]_PZN.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Potsdam, DEU

Website

www.aok.de

Kennung

DE275390265

Tätigkeit

Health

Lose (3)

LOT-0001

Bevacizumab

Open-house, non-exclusive pharmaceutical discount agreement for Bevacizumab (ATC L01FG01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-house, non-exclusive pharmaceutical discount agreement for Rituximab (ATC L01FA01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-house, non-exclusive pharmaceutical discount agreement for Trastuzumab (ATC L01FD01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

Vergabedetails

Veröffentlichungsdatum
11 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
100552-2026

Dokumente (2)

Ähnliche Ausschreibungen